HUYA Bioscience International Expands Senior Management Team
Appoints Yoshiki Shimamura as Vice President for Japan Operations
SAN DIEGO, June 30, 2015 /PRNewswire/ -- HUYA Bioscience International (HUYA) today announced an expansion of its Senior Management Team, with the appointment of Yoshiki Shimamura as Vice President for Japan Operations.
Mr. Shimamura has more than 25 years of experience in the biopharma industry and clinical research organizations in Japan and South Korea, including companies such as Novocure KK, Hospira Japan Co Ltd, Chong Kun Dang Pharmaceutical Co, Amgen and Taiho Pharmaceutical Co Ltd.
"It is a pleasure to welcome Yoshiki Shimamura to the HUYA team as we expand our activities in Japan," said Mireille Gillings, Ph.D., CEO of HUYA. "His broad experience in clinical operations, business development and marketing will help HUYA advance candidate products in the Japanese market. Here, we are making unprecedented use of the Tripartite Health Cooperation between China, Korea and Japan. Our aim is to accelerate approval of our products in Japan based on Chinese clinical trials data."
Educated in Japan, Mr. Shimamura has a B.Sc. in Molecular and Cell Biology from Saitama University, and an M.Sc. in Pharmaceutical Science from Chiba University. He has been a postgraduate researcher in Disease Biochemistry at Tokyo University of Pharmaceutical and Life Sciences, is currently a postgraduate researcher in Life Science Technology at Tokushima University, and aims to complete a Ph.D. in March 2016.
About HUYA Bioscience International
HUYA Bioscience International is a leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. Earlier this year, HUYA was named the winner of a Stevie® Award in the Health Products & Services and Pharmaceuticals category in the Asia-Pacific Stevie Awards.
www.huyabio.com
Contact details:
Jill Dawson, Ph.D.
Corporate Communications
HUYA Bioscience International
+1.919.360.8704
[email protected]
SOURCE HUYA Bioscience International
Share this article